RBC sees 40% upside in Biogen as pipeline momentum builds

RBC Capital Markets raised its price target on Biogen (BIIB) to $213 from $205, anticipating up to 40% upside driven by a robust pipeline of immunology and neurology assets entering a catalyst-rich phase from 2026. Despite ongoing pressure in its multiple sclerosis business, RBC believes Biogen's current valuation, around 2x sales and 8x forward earnings, significantly undervalues the potential of these advancing programs, including felzartamab and litifilimab, suggesting considerable appreciation with limited downside for the stock.

Analysis

RBC Capital Markets has issued a bullish update on Biogen, increasing its price target to $213 from $205, which implies a potential 40% upside from current levels. The core of this thesis is a re-evaluation of the company's pipeline, which is viewed as entering a catalyst-rich phase beginning in 2026. Unlike a single high-risk binary event, Biogen's pipeline features a diversified set of mid-to-late-stage programs in immunology and neurology that could collectively drive value. Key assets highlighted include felzartamab for rare kidney diseases and litifilimab for lupus, both of which have supportive Phase 2 data. This forward-looking potential is contrasted with the company's legacy multiple sclerosis business, which remains under pressure. RBC argues that the market is overly focused on the legacy portfolio, causing the stock to trade at a discounted valuation of approximately 2x sales and 8x forward earnings. This valuation, in RBC's view, significantly underappreciates the potential of the advancing pipeline and creates a favorable risk-reward profile with considerable appreciation potential and limited downside.

Key Decisions for Investors

• Investors should consider looking beyond the near-term pressures in the multiple sclerosis franchise and re-evaluate Biogen based on the long-term value of its diversified late-stage pipeline, which is expected to deliver key catalysts starting in 2026.
• Given the stock's valuation at around 2x sales and 8x forward earnings, the current share price may represent an attractive entry point for those believing in the pipeline's collective potential, which the broader market appears to be discounting.
• It is crucial to monitor clinical trial progress and upcoming data for key assets like felzartamab, litifilimab, and dapirolizumab pegol, as positive results will be essential to validate RBC's thesis and drive a re-rating of the stock.